CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017

SEATTLE, Feb. 23, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management plans to report its fourth quarter and full year 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:

Thursday, March 2
1:30 p.m. PT/4:30 p.m. ET/10:30 p.m. CET
1-877-719-9788 (domestic) 
+1 719-325-4802 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI BioPharma's website, www.ctibiopharma.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-888-203-1112 (domestic) or +1 719-457-0820 (international). The access code for the replay is 8629296. The telephone replay will be available until Thursday, March 9, 2017.

About CTI BioPharma

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe with respect to PIXUVRI^® and a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.

CTI BioPharma Contacts:

Ed Bell
+1 206-272-4345
ebell@ctibiopharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-fourth-quarter-and-full-year-2016-financial-results-on-march-2-2017-300412244.html

SOURCE CTI BioPharma Corp.